Ben Kozub has been working across marketing and sales leadership roles in the pharmaceutical and biotech sector for over 10 years. During this time, he has combined his passion for advocacy and portfolio brand management to help champion change and innovation across viral diseases both globally and in the US.
Ben’s career goals included moving HIV from a life-saving disease to a chronic condition and expanding PrEP as an essential tool in ending the HIV epidemic across the US. At Gilead Sciences, Ben was responsible for the build out of the US HIV Prevention business unit, leading to broad PrEP expansion among the healthcare providers and consumers, resulting in over 250 thousand active PrEP users by of the end of 2019. Before that, he led multiple global product launches for HIV treatment as the global marketing lead, obsoleting a multi-billion dollar portfolio with a new set of innovative medications with long term safety benefits.
Most recently, Ben moved onto a new role at Biomarin Pharmaceutical as Executive Director of Hemophilia brand management. If everything goes as planned, he will launch the first gene therapy approved for hemophilia A, which will certainly change the course of chronic treatment for a debilitating condition.
Ben is a graduate of Loyola University in Maryland and received his JD from Chicago- Kent College of Law. He currently lives in San Francisco and lives with his husband Scott – they got married in a week-long celebration last September with family and friends in Kauai. Ben continues to be an advocate for LGBTQIA+ right through his charitable efforts and is an active member of the Cornerstone Society in San Francisco.